US20210361734A1 - Compositions and methods for potentiating immune checkpoint inhibitor therapy - Google Patents

Compositions and methods for potentiating immune checkpoint inhibitor therapy Download PDF

Info

Publication number
US20210361734A1
US20210361734A1 US16/982,115 US201916982115A US2021361734A1 US 20210361734 A1 US20210361734 A1 US 20210361734A1 US 201916982115 A US201916982115 A US 201916982115A US 2021361734 A1 US2021361734 A1 US 2021361734A1
Authority
US
United States
Prior art keywords
larazotide
derivative
administered
checkpoint inhibitor
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/982,115
Other languages
English (en)
Inventor
Jay Madan
Sandeep Laumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
9 Meters Biopharma Inc
Original Assignee
9 Meters Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 9 Meters Biopharma Inc filed Critical 9 Meters Biopharma Inc
Priority to US16/982,115 priority Critical patent/US20210361734A1/en
Priority to US17/172,387 priority patent/US20210169968A1/en
Assigned to 9 METERS BIOPHARMA, INC. reassignment 9 METERS BIOPHARMA, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INNOVATE BIOPHARMACEUTICALS, INC.
Assigned to INNOVATE BIOPHARMACEUTICALS, INC. reassignment INNOVATE BIOPHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAUMAS, SANDEEP
Assigned to 9 METERS BIOPHARMA, INC. reassignment 9 METERS BIOPHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MADAN, Jay
Publication of US20210361734A1 publication Critical patent/US20210361734A1/en
Assigned to HIGH TRAIL SPECIAL SITUATIONS LLC reassignment HIGH TRAIL SPECIAL SITUATIONS LLC INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: 9 METERS BIOPHARMA, INC., NAIA RARE DISEASES, LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • suitable water insoluble polymers include, for example, lacquer, and acrylic and/or methacrylic ester polymers, polymers or copolymers of acrylate or methacrylate having a low quaternary ammonium content, or mixture thereof and the like.
  • suitable water insoluble polymers include, for example, EUDRAGIT RS®, EUDRAGIT RL®, EUDRAGIT NE®, polyvinyl esters, polyvinyl acetals, polyacrylic acid esters, butadiene styrene copolymers, and the like.
  • the delayed-release coating comprises a combination of any of the foregoing water insoluble polymers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US16/982,115 2018-03-19 2019-03-19 Compositions and methods for potentiating immune checkpoint inhibitor therapy Abandoned US20210361734A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/982,115 US20210361734A1 (en) 2018-03-19 2019-03-19 Compositions and methods for potentiating immune checkpoint inhibitor therapy
US17/172,387 US20210169968A1 (en) 2018-03-19 2021-02-10 Compositions and methods for potentiating immune checkpoint inhibitor therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644723P 2018-03-19 2018-03-19
PCT/US2019/022885 WO2019183036A1 (fr) 2018-03-19 2019-03-19 Compositions et méthodes pour potentialiser une thérapie par inhibiteur de point de contrôle immunitaire
US16/982,115 US20210361734A1 (en) 2018-03-19 2019-03-19 Compositions and methods for potentiating immune checkpoint inhibitor therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/022885 A-371-Of-International WO2019183036A1 (fr) 2018-03-19 2019-03-19 Compositions et méthodes pour potentialiser une thérapie par inhibiteur de point de contrôle immunitaire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/172,387 Continuation-In-Part US20210169968A1 (en) 2018-03-19 2021-02-10 Compositions and methods for potentiating immune checkpoint inhibitor therapy

Publications (1)

Publication Number Publication Date
US20210361734A1 true US20210361734A1 (en) 2021-11-25

Family

ID=67987489

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/982,115 Abandoned US20210361734A1 (en) 2018-03-19 2019-03-19 Compositions and methods for potentiating immune checkpoint inhibitor therapy
US17/239,056 Active US11278587B2 (en) 2018-03-19 2021-04-23 Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/239,056 Active US11278587B2 (en) 2018-03-19 2021-04-23 Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors

Country Status (2)

Country Link
US (2) US20210361734A1 (fr)
WO (1) WO2019183036A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to lymphocyte-associated protein - Tcytotoxic 4 (CTLA-4), preparations containing them and their uses
EP3755315A4 (fr) 2018-02-23 2022-01-05 9 Meters Biopharma, Inc. Composés et méthodes de traitement de la perméabilité des jonctions serrées
EP4013441A4 (fr) * 2019-08-16 2023-08-30 9 Meters Biopharma, Inc. Formulations de larazotide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777695B1 (fr) 2006-02-09 2018-09-12 Alba Therapeutics Corporation Preparations pour effecteurs de jonctions serrées
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8785374B2 (en) 2007-10-19 2014-07-22 Alba Therapeutics Corporation Inhibitors of mammalian tight junction opening
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
AU2009288730B2 (en) * 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US20120302505A1 (en) * 2011-04-21 2012-11-29 Fetzer Oliver S Cyclodextrin-based polymers for therapeutic delivery
CA2947149A1 (fr) * 2014-04-04 2015-10-08 Alba Therapeutics Corporation Procedes de traitement de la maladie coeliaque avec le larazotide
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
CA3052975A1 (fr) 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions et methodes destinees au traitement d'une maladie associee a la permeabilite de l'epithelium intestinal
CA3211208A1 (fr) * 2017-04-03 2018-10-11 Gusto Global, Llc Conception rationnelle d'agents biotherapeutiques d'origine microbienne
EP3755315A4 (fr) 2018-02-23 2022-01-05 9 Meters Biopharma, Inc. Composés et méthodes de traitement de la perméabilité des jonctions serrées
US12016889B2 (en) 2018-02-23 2024-06-25 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
US20210100868A1 (en) 2018-03-19 2021-04-08 North Carolina State University Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
WO2019199642A1 (fr) 2018-04-09 2019-10-17 Innovate Biopharmaceuticals Inc. Compositions et méthodes de traitement ou de prévention de l'hyperglycémie, de la résistance à l'insuline et de lésions d'organe associées
WO2020227341A1 (fr) 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions et procédés de traitement du syndrome de sjögren
EP4013441A4 (fr) 2019-08-16 2023-08-30 9 Meters Biopharma, Inc. Formulations de larazotide

Also Published As

Publication number Publication date
WO2019183036A1 (fr) 2019-09-26
US20210236586A1 (en) 2021-08-05
US11278587B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
US11278587B2 (en) Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors
CN112203669A (zh) 微生物组相关的免疫疗法
JP2020530494A (ja) 健康な腸バリアを維持及び回復するための組成物及び方法
JP2020530493A (ja) 腸内の抗生物質耐性菌を除菌するための組成物及び方法
EP3049070A2 (fr) Compositions et méthodes pour le traitement et la prophylaxie de maladies gastro-intestinales
US20210299481A1 (en) Compositions and methods for treating disease associated with permeability of intestinal epithelium
KR20200011619A (ko) 니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물
JP6554468B2 (ja) ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するため
US20210169968A1 (en) Compositions and methods for potentiating immune checkpoint inhibitor therapy
US20240263251A1 (en) Compositions and methods for providing secondary bile acids to a subject
KR20170122776A (ko) 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
Al-Toubah et al. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
WO2019183037A1 (fr) Compositions et méthodes pour le traitement ou la prévention des lésions gastro-intestinales associées aux traitements par les ains
Wong et al. Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses
US20240131082A1 (en) Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
CN113905749A (zh) 用于治疗免疫检查点抑制剂相关结肠炎的方法和组合物
CN115916235A (zh) 包含d-氨基酸的拉瑞唑来衍生物
WO2021142353A1 (fr) Compositions et méthodes pour le traitement de l'hépatite b (vhb) et de l'hépatite d (vhd)
KR20220006072A (ko) 이식편대숙주병의 치료를 위한 베타-락타마제 조성물
WO2022108870A1 (fr) Compositions et méthodes de traitement de la fibrose pulmonaire
WO2021163802A1 (fr) Utilisation de castalagine ou ses analogues permettant une efficacité anticancéreuse et permettant d'accroître la réponse aux inhibiteurs de point de contrôle immunitaire

Legal Events

Date Code Title Description
AS Assignment

Owner name: 9 METERS BIOPHARMA, INC., NORTH CAROLINA

Free format text: CHANGE OF NAME;ASSIGNOR:INNOVATE BIOPHARMACEUTICALS, INC.;REEL/FRAME:056396/0451

Effective date: 20200430

Owner name: INNOVATE BIOPHARMACEUTICALS, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAUMAS, SANDEEP;REEL/FRAME:056359/0869

Effective date: 20200415

Owner name: 9 METERS BIOPHARMA, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MADAN, JAY;REEL/FRAME:056359/0858

Effective date: 20210505

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: HIGH TRAIL SPECIAL SITUATIONS LLC, NEW JERSEY

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:9 METERS BIOPHARMA, INC.;NAIA RARE DISEASES, LLC;REEL/FRAME:063281/0653

Effective date: 20220715